

Consegna Annual General Meeting

Presentation by acting non-executive
Deputy Chairman Mr. Martin Rogers



CONSEGNA
DELIVERING INNOVATION

Welcome to the fiscal year 2011-2012 annual general meeting for Consegna Group. I am Martin Rogers, your non-executive Deputy Chairman, standing in for executive chairman Fabio Pannuti who unfortunately is delayed on business overseas. I have been with Consegna for 3 months and I know what it is like to turnaround a start-up Company.

Firstly, we would like to update shareholders with the progress with the business development activities regarding our BreatheAssist asset. As many of you will know, Consegna lodged an announcement prior to this meeting regarding the transaction negotiations with Triple A Holdings.

In essence, after exhaustive negotiations, the decision was made by the Board to suspend any further negotiations with Triple A. This has not been an easy decision but one the Board feels is best for the Company and for the BreatheAssist asset at this time.

We are aware that there is interest from other parties in the product and we will progress negotiations with these other interested parties globally with a focus still firmly set on the identifying a partner for BreatheAssist. Most important, the Board remains confident of achieving this outcome. Whilst we appreciate that there is strong interest in knowing the full details of these activities, they remain confidential in nature at this time and we are restricted in providing further details on the discussions underway.

It was our expectation that the BreatheAssist deal would be finalised by now; however your Board is committed to ensuring the terms of the agreement are in the best interest of Consegna shareholders in the short and longer term. We acknowledge that this is not an ideal situation and the market has clearly indicated its frustration at this delay; but we believe it will result in a stronger outcome.

As you know, BreatheAssist is a nasal dilator that increases airflow. The technology is a multi-application platform that enables a range of product offerings including potential application in sleep apnoea, snoring, disorders associated with a deviated septum, delivery of medicaments, for odour masking purposes, dust and pollen filtration and enhancing sports performance.

The elite sports product – we now know by the brand BO₂LT is designed specifically for athletes competing at the highest level internationally. The next two most advanced applications are for the snoring and sleep markets.

Over the last year we have made very good progress with the development of this product including:

- In market testing and trial by Australian Cyclist, Mark O'Brien who successfully used BreatheAssist in his victory in the Tour of Toowoomba and the Santos North Western Tour;
- Appointment of five time Olympic gold medallist, Sir Steve Redgrave as brand ambassador. Sir Redgrave is a living legend in the UK for his rowing achievements;
- A clinical trial at the Australian Catholic University commenced with results expected shortly;
- A first adopter program offered to shareholders allowing them to try and test BreatheAssist ahead of market launch which has resulted in more than 100 shareholders testing the device with 19 formal online survey responses; and
- Appointment of FDA approved manufacturer ChinaMed.

We were also pleased to complete our first major transaction which validates our Purchase, Package, Profit business model with the sale of Linguet to ASX-listed company Imugene. Linguet is a drug delivery technology, where the tablet is placed under the tongue rather than swallowed, and allowing faster absorption of the drug into the blood stream. The Linguet technology system allows a larger amount of the active ingredient of the drug to be absorbed more quickly, resulting in smaller doses, lower toxicity, reduced side-effects and improved patient compliance.

Imugene is pursuing initial targets for commercialisation of Linguet in the nutraceutical market with the intention of generating early cash flow. As a result of the transaction, Consegna has a 29% shareholding in Imugene.

In late October, Consegna announced that following a comprehensive review process it elected not to proceed with the acquisition of the Aspen Medisys assets. This decision was based on the longer than expected development and commercialisation timeframe, higher than expected required investment, and weaker intellectual property position.

The due diligence process is an important one for a business like ours and whilst we had great hope and expectation from the Aspen business, in the end our internal review process identified a number of concerns and it was this Board's strong belief that continuing with the transaction was not in the best interest of the shareholders and the company. Having run a biotechnology company myself, I can personally attest that these decisions are difficult but very necessary.

Finally, we acknowledge recent erosion of our share price. These are tough times and we rely on support of our shareholders to make the Company successful. We understand that investors are frustrated and can only give you our reassurances that we are continuing to advance our products as quickly as possible. With BreatheAssist market ready, this remains our number one priority and as such our focus is primarily on this program. With the majority of R&D completed on BO₂LT, a manufacturer in place and much of the preparation for market launch complete, we are entering a period in which the Company is applying a program of cost containment. As previously announced, this includes a reduction in administrative, employee and consultant fees and includes the voluntary agreement by the Executive Chairman to take a 50% reduction in his salary. We are managing this process prudently but not to the detriment of getting BreatheAssist to market and we will continue to keep the market apprised of our progress.

Finally, I'd like to thank retiring non-executive director Mr Brendan Fleiter for his services to the board over the last 12 months. Mr Fleiter won't stand for re-election today. We acknowledge and appreciate his contribution. As the newest member of the Consegna Board I know I can speak to my fellow directors in reassuring investors that we are committed to developing a business that in time grows in value and delivers on our promise of extracting value from the assets we have acquired. We are looking forward to a productive 2013 and thank you for your attendance.

Thank you.

Consegna Group AGM Presentation November 2012



CONSEGNA
DELIVERING INNOVATION

Dr Nicholas Ede (CTO)

Safe Harbour Statement


This document contains certain forward-looking statements, relating to CGP's business, which can be identified by the use of forward-looking terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.

There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects.

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. CGP is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

Four product programs

Each of the Conseгна technologies has application across a range of market opportunities:

	BreatheAssist™ Multifunctional nasal dilation product	Vibrovein Vibrating device, attaches to syringe to reduce pain and resistance	Linguet™ Drug delivery technology	Aspen Medisys Thermotherapy cancer treatment
Application	 <ul style="list-style-type: none"> • Sports performance • Snoring reduction • Airborne pollutant filtration • Drug Delivery 	 <ul style="list-style-type: none"> • Acute care • Home care • Triage • Pathology • Blood banking • Surgical • Sclerotherapy 	 <ul style="list-style-type: none"> • All pill-based medication • Consumer • Generic • Branded pharmaceuticals 	 <ul style="list-style-type: none"> • Medical device • Human health • Veterinary health
Stage	Market launch in Q12013	Market launch in Q42013	Asset sold to ASX:IMU July 2012	Discontinued 31st Oct 2012
Market opportunity	First target sports market	First target cosmetic market	First target vitamin D market	



Packaging BreatheAssist™ for Profit

BreatheAssist™

BreatheAssist™ is a nasal dilator that provides an innovative solution for those who suffer from nasal congestion, obstruction and snoring and contributes to enhanced sports performance

- **2011 Consegna (Helicon) acquires asset**

- ✗ Asset 10 years in development
- ✗ Focused on the science story, not the market story

- **Focused team applies Consegna model in Feb 2012**

- ✓ 9 month gestation period to ready asset for global launch
- ✓ Designed in response to feedback from elite and amateur athletes
- ✓ Tested by Australian Professional Road Cyclist, **Mark O'Brien** with reported increased performance.



Professional Road Cyclist, Mark O'Brien



The BreatheAssist™ Product Range – creating a house of brands



BO₂LT
Sport market




HARMO₂NY
Snoring market



AirFX
Filtration
market


BreatheAssist™ key trial conclusions

- **Clinical studies have demonstrated BreatheAssist™'s effectiveness compared to competitors**
- A 2005 trial showed:
 - ✓ The BreatheAssist™ Dilator achieved 175-cc/second increase in airflow compared to the Baseline and BreatheRight nasal strip
 - ✓ BreatheAssist™ is proven to provide a substantial increase in nasal airflow



BreatheAssist™ Sports – clinical trial

- **Independent study at Australian Catholic University underway**
- 20 recreationally active males
- Study measuring impact of nasal dilator on breathing, energy and output in heavy exercise
- Study seeking to validate and confirm the experience of Mark O'Brien, Australian cyclist who used BreatheAssist in the Cycling Australia Subaru National Road Series



I wish I had it when I was an athlete, I might have been able to carry on for a sixth gold medal, and not stop at five.

*Sir Steve Redgrave – July 2012
5 times Olympic Gold Medalist (Rowing)*

De-risking the technology to optimise value

A rigorous approach to mitigating risk and creating value for the intended licensee



AUSTRALIAN CYCLING

An economic overview

CYCLE TOURISM

\$254 million

Events and tourist trails generate \$254 million a year in Australia⁽⁴⁾.



INFRASTRUCTURE

\$40 million

\$40 million Commonwealth stimulus package is generating \$80 million local govt investment, and creating 600km of bike paths and 1314 jobs⁽⁸⁾.



CONGESTION

\$13 billion

Congestion is projected to cost Australia \$13 billion in 2011⁽¹⁾. 50% of car trips are less than 5 km.



The National Cycling Strategy aims to double the numbers of Australians riding by 2016.

PARTICIPATION

4 million

18% of Australians cycle in a typical week, 1.6 million use their bikes for transport⁽⁷⁾.



MARKET

\$1 billion

Bike and accessories are worth \$1 billion a year, generating \$100 million gst revenue⁽³⁾.



ENVIRONMENT

\$9.6 billion

Car trips cost 5.9¢ a km in CO2, air, water and noise pollution^(2a). In 2010 we drove cars more than 163 million kms^(2b).



INACTIVITY

\$13.8 billion

Inactivity costs Australia \$13.8 billion a year⁽⁵⁾. Everyday cycling can provide recommended activity levels and reduce this cost.



EMPLOYMENT

10,000

The Australian bicycle industry employs 10,000 people and generates \$139 million income tax revenue⁽³⁾.

LOCAL BIKE SHOP



WORK PERFORMANCE

\$61.9 million

Regular bicycle riders take one less sick day than non-riders^(6a), saving businesses \$61.9 million a year^(6b).



OWNERSHIP


4.2 million households

More than half of Australian households⁽⁷⁾ have at least one bike.



A US mass market opportunity

This year more than 43 million Americans will participate in the sport of bicycle riding, and 5.6 million of these enthusiasts will ride more than 110 days



Source:
Active Marketing Group 2007



What do cyclists pay for?

WANT TO RIDE LIKE CADEL? TOTAL COST \$21,553

HELMET
Bell Volt
\$249

SUNGLASSES
Oakley Radar
\$299

COMPUTER
SRM PowerMeter PowerControl 7
\$4975

GLOVES
BMC team
\$69

CLOTHES
BMC jersey
\$169
BMC bib nix
\$199

BIKE (STANDARD)
BMC SLR01 Team Machine
\$7995

WHEELS (EXTRA)
Easton EC90SL
\$3799

RUNNING GEAR (EXTRA)
Dura-Ace Di2 groupset
\$3500


SHOES
Diadora Proracer 3
\$299



Cycling is just the tip of the Sports Market iceberg!




What type of sporting or exercise activity were you doing when you used the BOLT?




Shareholder Trial Survey Responses

Usage and Time

How long did you wear the BOLT when undertaking the exercise?




Thinking about the process of inserting BOLT into your nose, how do you rate the material it is made from?



Shareholder Trial Survey Responses

Fit and Feel


How aware were you of the BOLT whilst you were exercising?



Shareholder Trial Survey Responses

Did it work?


Thinking about the BOLT, to what extent do you agree or disagree with these statements




Shareholder Trial Survey Responses

Does it have a market?

If BOLT were available today, how likely would you be to buy it?



If BOLT were available today, how likely would you be to recommend it to others?





The difference between first and second?
A deep breath

Introducing BO₂LT. A new medical technology that will change the way you breathe forever. Clinically proven to increase airflow, BO₂LT will deliver you more air when you need it most. Don't just run, BO₂LT

BO₂LT